Coeptis Therapeutics Holdings Inc. (COEP) Dividend History

Coeptis Therapeutics Holdings Inc. (COEP) is a biotechnology company focused on developing innovative therapies for conditions with unmet medical needs. The company's mission centers on leveraging its proprietary delivery platforms and scientific expertise to advance treatments in areas such as oncology and infectious diseases. Coeptis aims to improve patient outcomes through novel medications and strategic collaborations within the pharmaceutical industry.

Dividend History

Coeptis Therapeutics Holdings Inc. currently does not pay dividends

Company News

COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing

COEPTIS and MarketLeverage have partnered to integrate AI technology with performance-based affiliate marketing strategies, aiming to provide advanced automation, data-driven insights, and seamless campaign optimization for affiliates, brands, and marketers.

GlobeNewswire Inc.
Coeptis Therapeutics Leverages Artificial Intelligence and Blockchain for Next-Generation Innovation

Coeptis Therapeutics is expanding its technological initiatives to include artificial intelligence and blockchain solutions, aiming to enhance operational efficiency and drive innovation in the pharmaceutical industry.

Benzinga
Coeptis Therapeutics Announces Reverse Stock Split

Coeptis Therapeutics announced a 1-for-20 reverse stock split to help meet the minimum bid price requirement for maintaining its Nasdaq Capital Market listing.

Benzinga
Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries

Coeptis Therapeutics has executed a binding letter of intent to acquire NexGenAI Affiliates Network, a platform that offers AI-powered marketing software and robotic process automation capabilities. The acquisition aims to enhance Coeptis' operational efficiency and create new growth opportunities.

Benzinga
Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development

Coeptis Therapeutics announced that results from their Phase 1 study evaluating DVX201, an allogeneic natural killer (NK) cell therapy, for the treatment of patients hospitalized with COVID-19 have been accepted for publication. The study demonstrated the safety and feasibility of DVX201 as a potential treatment for patients with active SARS-CoV-2 infections.

Benzinga

Dividend data last updated 06/07/2025 22:01:48 UTC